

TABLE I  
 EFFECT OF METHOTREXATE DERIVATIVES ON ENZYMES AND BACTERIAL GROWTH

Compd	Concn for 50% inhib, $\mu\text{g}/\text{ml}$				
	Dihydrofolate reductase	Thymidylate synthetase	<i>S. faecalis</i>	<i>P. cerevisiae</i>	<i>L. Casei</i>
Methotrexate	9 (1) <sup>a</sup>	45,000 (1)	0.15 (1)	60 (1)	0.01 (1)
Dihydropmethotrexate	16 (0.56)	1,125 (40)	0.011 (1.4)	24 (2.5)	0.008 (1.3)
Tetrahydropmethotrexate	46 (0.20)	2,250 (20)	0.047 (3.4)	68 (1)	0.056 (0.18)

<sup>a</sup> Numbers in parentheses indicate potency relative to methotrexate.

Thymidylate synthetase from *Escherichia coli* B<sup>12</sup> was provided by Dr. M. Friedkin and Miss E. Donovan. Dihydrofolate reductase was obtained from a mouse tumor I.1210-C95.<sup>9</sup> The enzymes were assayed as described.<sup>9</sup>

Fractions to be assayed microbiologically were diluted in potassium ascorbate (6 mg/ml, pH 6.0) and added aseptically to the assay medium.<sup>13</sup> The final concentration of ascorbate in the assay

(12) M. Friedkin, E. J. Crawford, E. Donovan, and E. J. Pastore, *J. Biol. Chem.*, **237**, 3811 (1962).

was 0.6 mg/ml. *Lactobacillus casei* (ATCC 7469), *Streptococcus faecalis* (ATCC 8043), and *Pediococcus cerevisiae* (ATCC 8084) were grown on the corresponding Difco assay media for 24 hr at 37°. The *L. casei* and *S. faecalis* media contained 1  $\mu\text{g}$  of folate/ml and the *P. cerevisiae* medium contained 1  $\mu\text{g}$ /ml of calcium *dl*-1,5-formyltetrahydrofolate. Growth was determined turbidimetrically.

(13) H. A. Bakerman, *Anal. Biochem.*, **2**, 558 (1961).

## New Compounds

### Synthesis of 6,8-Dibromo-3-substituted 2-(N,N-Dialkyl- (or N-Piperidino)-carboxamidomethylthio)-4(3H)-quinazolinones as Antimalarials

P. N. BHARGAVA AND M. R. CHAURASIA,


Department of Chemistry, Banaras Hindu University,  
Varanasi-5, India

Received January 11, 1968

The antimalarial activity of febrifugine, an alkaloid of a 3-substituted 4(3H)-quinazolinone structure, has prompted the preparation and testing of a number of quinazolines,<sup>1</sup> and several patent claims have been made on quinazolines as intermediates for potential antimalarials.<sup>2</sup> Compounds having the side chain  $-\text{CH}_2\text{COCH}_2\text{R}$  (where R =  $\omega$ -N-morpholylpropyl or  $\omega$ -N-piperidyl-*n*-butyl) at position 3 of the 4(3H)-quinazolinone nucleus were shown to have significant antimalarial activity.<sup>3</sup>

Since the activity of these compounds is influenced by various substituents and their positions, a number of derivatives have been synthesized in the course of our previous investigations<sup>4</sup> by introducing some new side chains into some 6,8-dibromo-3-substituted 2-mercapto-3-aryl- (or alkyl)-4(3H)-quinazolones as antimalarials having the general structure 1.

The standard tests for antimalarial activity in chicks infected with *Plasmodium gallinaceum* so far reported on these compounds indicate that they have no significant value pharmacologically.



I

(1) F. W. Wiselogle, Ed., "A Survey of Antimalarial Drugs 1941-1945," Edward Brothers, Ann Arbor, Mich., 1946.

(2) B. R. Baker and M. V. Querry, U. S. Patent 2,796,417 (1957); *Chem. Abstr.*, **52**, 459 (1958); B. R. Baker, U. S. Patent 2,811,542 (1957); *Chem. Abstr.*, **52**, 5488 (1958).

(3) O. Y. Magidson and Y. K. Lu, *Zh. Obshch. Khim.*, **29**, 2843 (1959); *Chem. Abstr.*, **54**, 12144 (1960).

(4) P. N. Bhargava and M. R. Chaurasia, *J. Med. Chem.*, **11**, 101 (1968).

### Experimental Section

**6,8-Dibromo-3-phenyl-2-(N-piperidinocarboxamidomethylthio)-4(3H)-quinazolinone.**—N-Chloroacetyl-piperidine (2 ml) dissolved in EtOH, was added to a solution of 6,8-dibromo-2-thio-3-phenyl-2,4(1H,3H)-quinazolinone (4.5 g) in EtOH-NaOH. The resulting mixture was stirred thoroughly for 2 hr at 23-25°. On cooling the solution to 0° a crystalline product was formed. It was filtered and washed (H<sub>2</sub>O, EtOH). Recrystallization of the product from EtOH-Me<sub>2</sub>CO (1:2) gave a pure analytical sample.

Similarly various 6,8-dibromo-3-substituted 2-(N,N-dialkyl- (or N-piperidino)-carboxamidomethylthio)-4(3H)-quinazolones have been prepared (see Tables I-V).

TABLE I  
6,8-DIBROMO-3-SUBSTITUTED 2-(N,N-METHYLPHENYL-CARBOXAMIDOMETHYLTHIO)-4(3H)-QUINAZOLINONES<sup>a</sup>

R	% yield	Mp, °C	Formula <sup>b</sup>
C <sub>6</sub> H <sub>5</sub>	58	87	C <sub>23</sub> H <sub>17</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	40	246	C <sub>24</sub> H <sub>15</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	50	83	C <sub>24</sub> H <sub>15</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	55	98	C <sub>24</sub> H <sub>15</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	50	95	C <sub>23</sub> H <sub>14</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	55	104	C <sub>24</sub> H <sub>15</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>p</i> -OC <sub>2</sub> H <sub>5</sub> C <sub>6</sub> H <sub>4</sub>	60	218	C <sub>25</sub> H <sub>17</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>n</i> -C <sub>4</sub> H <sub>9</sub>	35	200	C <sub>27</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	53	221	C <sub>24</sub> H <sub>16</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S

<sup>a</sup> Crystallization solvent: EtOH. <sup>b</sup> All compounds were analyzed for N, S. The analytical results were within  $\pm 0.3\%$  of the calculated values.

TABLE II  
6,8-DIBROMO-3-SUBSTITUTED 2-(N,N-ETHYLPHENYL-CARBOXAMIDOMETHYLTHIO)-4(3H)-QUINAZOLINONES<sup>a</sup>

R	% yield	Mp, °C	Formula <sup>b</sup>
C <sub>6</sub> H <sub>5</sub>	65	106	C <sub>25</sub> H <sub>19</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	50	105	C <sub>25</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	40	295 dec	C <sub>25</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	75	121	C <sub>25</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -ClC <sub>6</sub> H <sub>4</sub>	45	248 dec	C <sub>24</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	65	110	C <sub>24</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	55	114	C <sub>25</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>p</i> -OC <sub>2</sub> H <sub>5</sub> C <sub>6</sub> H <sub>4</sub>	70	104	C <sub>26</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	35	258 dec	C <sub>25</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S

<sup>a</sup> Crystallization solvent: EtOH. <sup>b</sup> All compounds were analyzed for Br, N. The analytical results were within  $\pm 0.3\%$  of the calculated values.

TABLE III  
6,8-DIBROMO-3-SUBSTITUTED 2-(N,N-BENZYLPHENYL-  
CARBOXAMIDOMETHYLTHIO)-4(3H)-QUINAZOLINONES<sup>a</sup>

R	% yield	Mp, °C	Formula <sup>b</sup>
C <sub>6</sub> H <sub>5</sub>	70	113	C <sub>29</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	45	245	C <sub>30</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	50	84	C <sub>30</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	60	88	C <sub>30</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -ClC <sub>6</sub> H <sub>4</sub>	65	103	C <sub>29</sub> H <sub>20</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	55	96	C <sub>29</sub> H <sub>20</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	65	93	C <sub>30</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>p</i> -OC <sub>2</sub> H <sub>5</sub> C <sub>6</sub> H <sub>4</sub>	75	111	C <sub>31</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>n</i> -C <sub>4</sub> H <sub>9</sub>	35	219	C <sub>27</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	40	238 dec	C <sub>30</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S

<sup>a</sup> Crystallization solvent: EtOH. <sup>b</sup> All compounds were analyzed for Br, N. The analytical results were within ±0.3% of the calculated values.

TABLE IV  
6,8-DIBROMO-3-SUBSTITUTED 2-(N,N-DIETHYL-  
CARBOXAMIDOMETHYLTHIO)-4(3H)-QUINAZOLONES<sup>a</sup>

R	% yield	Mp, °C	Formula <sup>b</sup>
C <sub>6</sub> H <sub>5</sub>	60	187	C <sub>20</sub> H <sub>19</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	50	162	C <sub>21</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	30	275 dec	C <sub>21</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	55	188	C <sub>21</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -ClC <sub>6</sub> H <sub>4</sub>	40	270 dec	C <sub>20</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	35	295 dec	C <sub>20</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	45	>320	C <sub>21</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>p</i> -OC <sub>2</sub> H <sub>5</sub> C <sub>6</sub> H <sub>4</sub>	35	235 dec	C <sub>22</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
CH <sub>3</sub>	25	305 dec	C <sub>18</sub> H <sub>17</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
C <sub>2</sub> H <sub>5</sub>	30	>320	C <sub>18</sub> H <sub>19</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>n</i> -C <sub>4</sub> H <sub>9</sub>	45	285 dec	C <sub>18</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	25	248 dec	C <sub>21</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S

<sup>a</sup> Crystallization solvent: Me<sub>2</sub>CO-EtOH-EtOAc (3:1:1). <sup>b</sup> All compounds were analyzed for N, S. The analytical results were within ±0.3% of the calculated values.

TABLE V  
6,8-DIBROMO-3-SUBSTITUTED 2-(N-PIPERIDINO-  
CARBOXAMIDOMETHYLTHIO)-4(3H)-QUINAZOLINONES<sup>a</sup>

R	% yield	Mp, °C	Formula <sup>b</sup>
C <sub>6</sub> H <sub>5</sub>	60	240	C <sub>21</sub> H <sub>19</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	35	238 dec	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	40	270 dec	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	45	250 dec	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>m</i> -ClC <sub>6</sub> H <sub>4</sub>	50	268 dec	C <sub>21</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	55	260 dec	C <sub>21</sub> H <sub>18</sub> Br <sub>2</sub> ClN <sub>3</sub> O <sub>2</sub> S
<i>p</i> -OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	65	116	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
<i>p</i> -OC <sub>2</sub> H <sub>5</sub> C <sub>6</sub> H <sub>4</sub>	50	290 dec	C <sub>23</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
CH <sub>3</sub>	30	280 dec	C <sub>16</sub> H <sub>17</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
<i>n</i> -C <sub>4</sub> H <sub>9</sub>	25	305 dec	C <sub>19</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S
C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	35	275 dec	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S

<sup>a</sup> Crystallization solvent: Me<sub>2</sub>CO-EtOH (2:1). <sup>b</sup> All compounds were analyzed for N, S. The analytical results were within ±0.3% of the calculated values.

**6,8-Dibromo-3-benzyl-2-carboxymethylthio-4(3H)-quinazolinone.**—An equimolar quantity of sodium monochloroacetate was added to a 6,8-dibromo-2-thio-3-benzyl-2,4(1H,3H)-quinazolinone in EtOH-NaOH, and the mixture was shaken for 6 hr. It was acidified with HCl, the precipitate obtained was dissolved in NaHCO<sub>3</sub>, filtered, and reprecipitated with HCl. The product was crystallized (EtOH); yield 60%, mp 237. *Anal.* (C<sub>17</sub>H<sub>12</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S) C, H, N, S.

**6,8-Dibromo-3-phenyl-1-ethyl-2-thio-2,4(1H,3H)-quinazolinone.**—A mixture of 3,5-dibromo-N-ethylanthranilic acid (1.6 g), pyridine (0.4 g), EtOH (5 ml), and phenyl isothiocyanate (0.68 g) was refluxed at 90° for 6 hr. The crystalline product was filtered and recrystallized from C<sub>6</sub>H<sub>6</sub> and EtOH mixture (3:1) to give 60% yield of the required product, white needles, mp 242°. *Anal.* (C<sub>18</sub>H<sub>12</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S) C, H, N.

**Acknowledgments.**—Sincere thanks are due to the authorities of the Banaras Hindu University for providing the necessary facilities, the authorities of the Indian Institute of Communicable Diseases, Delhi, for carrying out the pharmacological tests, and the University Grants Commission, New Delhi, for the award of a Junior Research Fellowship to one of the authors (M. R. C.).

#### 4-Dialkylaminoalkylamino-3-phenylpyridines<sup>1</sup>

WARREN G. DUNCAN AND DAVID W. HENRY

Department of Pharmaceutical Chemistry,  
Stanford Research Institute, Menlo Park, California 94025

Received February 26, 1968

As part of a program devoted to the synthesis of novel anti-malarial agents we have prepared the series of N-substituted 3-phenyl-4-aminopyridines listed in Table I. Treatment of 3-phenylpyridines bearing appropriate substituents in the 4 position with the diamines corresponding to the side chains was the general synthetic approach. The oily free bases were characterized by their nmr spectra and as oxalic acid salts. None of the tabulated compounds were active when screened against *Plasmodium berghei* in mice.<sup>2</sup>

TABLE I  
4-DIALKYLAMINOALKYLAMINO-3-PHENYLPYRIDINE DIOXALATES

n	R	Mp, °C	Formula	Analyses <sup>3</sup>
2	Et	177–178	C <sub>17</sub> H <sub>23</sub> N <sub>3</sub> ·2H <sub>2</sub> C <sub>2</sub> O <sub>4</sub>	C, H, N
3	Et	155–157	C <sub>18</sub> H <sub>25</sub> N <sub>3</sub> ·2H <sub>2</sub> C <sub>2</sub> O <sub>4</sub>	C, H, N
4	Et	140–141	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> ·2H <sub>2</sub> C <sub>2</sub> O <sub>4</sub>	C, H, N
5	Et	162–164	C <sub>20</sub> H <sub>29</sub> N <sub>3</sub> ·2H <sub>2</sub> C <sub>2</sub> O <sub>4</sub>	C, H, N
6	Me	145–148	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> ·2H <sub>2</sub> C <sub>2</sub> O <sub>4</sub>	C, H, N

#### Experimental Section<sup>3</sup>

**4-Methoxy-3-phenylpyridine** was prepared by the procedure of Ahmad and Hey.<sup>4</sup> The improved Gomberg reaction procedure of Cadogan<sup>5</sup> was used in the final step of the sequence.

**4-Hydroxy-3-phenylpyridine.**—4-Methoxy-3-phenylpyridine (15 g, 81 mmoles) was refluxed for 3 hr with 100 ml of 58% HI. The solution was cooled, diluted with 80 ml of H<sub>2</sub>O, and treated with Na<sub>2</sub>SO<sub>3</sub> until the dark color had faded to orange-yellow. The solution was made slightly alkaline, and the oily solid that came out of solution was collected and washed thoroughly with Et<sub>2</sub>O. The filtrate was extracted with Et<sub>2</sub>O to remove unhydrolyzed starting material. From the ethereal washings and extracts was recovered 4.86 g (32%) of starting material. The remaining crystalline solid (5.3 g, 56% yield based on recovered starting material) had mp 210–225°. Recrystallization from hot H<sub>2</sub>O gave pure product, mp 228–230°. *Anal.* (C<sub>11</sub>H<sub>9</sub>NO) C, H.

**4-Chloro-3-phenylpyridine.**—4-Hydroxy-3-phenylpyridine (0.20 g, 1.17 mmoles) was refluxed for 1.5 hr with ca. 2 ml of POCl<sub>3</sub>; the mixture was cooled and poured into ice water.

(1) This work was supported by the U. S. Army Medical Research and Development Command under Contract No. DA-49-193-MD-2750. This is contribution number 343 from the Army Research Program on Malaria.

(2) The anti-malarial tests were performed by Dr. Leo Rane of the University of Miami [T. S. Osdene, P. B. Russell, and L. Rane, *J. Med. Chem.*, **10**, 431 (1967)]. Testing results were supplied through the courtesy of Dr. David P. Jacobus of the Walter Reed Army Institute of Research.

(3) Melting points were taken in a Mel-Temp apparatus and are corrected. Microanalyses were performed by the Stanford Research Institute Analytical Laboratories. Where analyses are indicated only by the symbols of the elements, analytical results obtained for those elements were within ±0.4% of the theoretical values.

(4) Y. Ahmad and D. Hey, *J. Chem. Soc.*, 4516, 4521 (1954).

(5) J. Cadogan, *ibid.*, 4257 (1962).